Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia

Abstract

Background The allergic phenotype is responsible for more than 50% of severe asthma cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe allergic asthma (SAA). This study was aimed to describe the real-world effectiveness of omalizumab in adult and pediatric patients with SAA in Colombia. Methods This was an observational, non-interventional, retrospective study. Data from patients with SAA that received at least one month of treatment with omalizumab was obtained from medical records at eight sites in Colombia. Time-zero (t − 0) was defined as the date of initiation of omalizumab, and data was gathered for a 12-month period before t − 0 and a 12-month period after t − 0. Clinical outcomes, including exacerbations, were assessed at 6 and 12 months. Effectiveness of omalizumab was evaluated in terms of the reduction of the risk of exacerbations (annualized rate). Results We included 143 patients with SAA. There was a decrease of 72.4% of the annualized rate of clinically significant asthma exacerbations during the year after omalizumab (from 1.74 before to 0.48 after) with a substantial reduction of the risk of exacerbations by 56.7% (RR [95% CI] 0.43 [0.30–0.63] p < 0,001). Conclusion The use of omalizumab in Colombia as a treatment for SAA notably reduced the risk of clinically significant exacerbations. This study is the first to evaluate omalizumab real-life effectiveness in pediatric and adult patients in the country.

Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract

“…2023;17 (20): [68][69][70][71][72][73][74][75][76][77][78][79][80][81][82][83] Chronic pulmonary diseases ВВЕДЕНИЕ Омализумаб -первое моноклональное антитело, которое было одобрено и зарегистрировано регуляторными органами как лекарственный препарат для лечения аллергической бронхиальной астмы (БА). Впервые о концепции анти-IgE-терапии было заявлено в конце 1980-х гг.…”

“…Вторая декада XXI в. ознаменовалась исследованиями в реальной клинической практике, результаты которых подтвердили данные РКИ (табл. 3) [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. При применении омализумаба более 6 мес.…”

Asthma Phenotypes in the Era of Personalized Medicine

“…Numerous real-world studies have emerged over eighteen years of utilizing Omalizumab, shedding light on its effectiveness [150]. These investigations have underscored that omalizumab notably diminishes the frequency of exacerbations and is a preventive measure against their occurrence [151][152][153][154][155][156]. Furthermore, it enhances asthma control by mitigating daily symptoms, reducing activity constraints [153], and lessening rescue medication requirements [154,156].…”

“…These investigations have underscored that omalizumab notably diminishes the frequency of exacerbations and is a preventive measure against their occurrence [151][152][153][154][155][156]. Furthermore, it enhances asthma control by mitigating daily symptoms, reducing activity constraints [153], and lessening rescue medication requirements [154,156]. Remarkably, healthcare resources, encompassing emergency room visits and hospitalizations for lung function concerns, have also demonstrated improvement [150,[157][158][159].…”

Asthma Phenotypes in the Era of Personalized Medicine

“…Several studies of real-world experience with omalizumab have been developed after eighteen years of experience with the drug [126] in which omalizumab has been shown to significantly decrease the rate of exacerbations and prevent their occurrence [127][128][129][130][131]. Improves asthma control by reducing daily symptoms, activity limitations [129], and the need for rescue medications [130,132]. The utilization of health resources, such as visits to the emergency room and hospitalizations for lung function, has also been reported to improve [130,[133][134][135].…”